# EDGAR Filing Document

**Accession Number:** 0001038277
**File Stem:** 0001437749-25-026370
**Filing Date:** 2025-8
**Character Count:** 120854
**Document Hash:** 178f6d46276cecd82d5d1328ba5ff5e1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-25-026370.hdr.sgml**: 20250813

**ACCESSION NUMBER**: 0001437749-25-026370

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 56

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250813

**DATE AS OF CHANGE**: 20250813

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** INTERNATIONAL ISOTOPES INC
- **CENTRAL INDEX KEY:** 0001038277
- **STANDARD INDUSTRIAL CLASSIFICATION:** INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, AND CONTROL [3823]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 742763837
- **STATE OF INCORPORATION:** TX
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-22923
- **FILM NUMBER:** 251209264

**BUSINESS ADDRESS:**
- **STREET 1:** 4137 COMMERCE CIRCLE
- **CITY:** IDAHO FALLS
- **STATE:** ID
- **ZIP:** 83401
- **BUSINESS PHONE:** 2085245300

**MAIL ADDRESS:**
- **STREET 1:** 4137 COMMERCE CIRCLE
- **CITY:** IDAHO FALLS
- **STATE:** ID
- **ZIP:** 83401

?xml version='1.0' encoding='ASCII'? inis20250630_10q.htm

[**Table of Contents**](#toc)

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2025

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____________ to _______________

Commission file number:

000-22923

**INTERNATIONAL ISOTOPES INC.**

*(Exact name of registrant as specified in its charter)*

---

| | |
|:---|:---|
| **Texas** | **74-2763837** |
| *(State or other jurisdiction of*<br> *incorporation or organization)* | *(IRS Employer Identification No.)* |

---

**4137 Commerce Circle**

**Idaho Falls, Idaho, 83401**

*(Address of principal executive offices, including zip code)*

**(208) 524-5300**

*(Registrant*'*s telephone number, including area code)*

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Large accelerated filer ☐ | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accelerated filer ☐ |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-accelerated filer ☒ | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Smaller reporting company ☒ |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Emerging growth company ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

As of August 8, 2025, the number of shares of common stock, $0.01 par value, outstanding was 528,104,105.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1

------

[**Table of Contents**](#toc)

**INTERNATIONAL ISOTOPES INC.**

**FORM 10-Q**

**For The Quarter Ended June 30, 2025**

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
|  |  | **<u>Page No.</u>** |
| **PART I** – **FINANCIAL INFORMATION** | **PART I** – **FINANCIAL INFORMATION** |  |
| Item 1. | Financial Statements |  |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; [<u>Unaudited Condensed Consolidated Balance Sheets at June 30, 2025 and December 31, 2024</u>](#bs) | [3](#bs) |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; [<u>Unaudited Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2025 and 2024</u>](#ops) | [4](#ops) |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; [<u>Unaudited Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2025 and 2024</u>](#cf) | [5](#cf) |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; [<u>Unaudited Condensed Consolidated Statement of Stockholder</u><u>'</u><u>s (Deficit) Equity for the</u>](#se)[<u>Three</u>](#cf)[<u>and Six Months Ended June 30, 2025 and 2024</u>](#se) | [6](#se) |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; [Notes to Unaudited Condensed Consolidated Financial Statements](#notes) | [8](#notes) |
| Item 2. | [<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>](#mda) | [8](#mda) |
| Item 4. | [<u>Controls and Procedures</u>](#controls) | [28](#controls) |
| **PART II** – **OTHER INFORMATION** | **PART II** – **OTHER INFORMATION** |  |
| Item 1. | [<u>Legal Proceedings</u>](#legal) | [28](#legal) |
| Item 1A. | [<u>Risk Factors</u>](#risk) | [28](#risk) |
| Item 2. | [<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>](#unregistered) | [28](#unregistered) |
| Item 5. | [Other Information](#Other) | [28](#unregistered) |
| Item 6. | [<u>Exhibits</u>](#exhibits) | [29](#exhibits) |
| [<u>Signatures</u>](#sigs) | [<u>Signatures</u>](#sigs) | [30](#sigs) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2

------

[**Table of Contents**](#toc)

**PART I** – **FINANCIAL INFORMATION**

**ITEM 1. FINANCIAL STATEMENTS**

**INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES**

**Condensed Consolidated Balance Sheets**

**(unaudited)**

---

| | | |
|:---|:---|:---|
|  | ***June 30,*** | ***December 31,*** |
|  | ***2025*** | ***2024*** |
| Assets |  |  |
| Current assets |  |  |
| &nbsp;&nbsp;&nbsp; Cash and cash equivalents | $1859424 | $1945523 |
| &nbsp;&nbsp;&nbsp; Accounts receivable | 1732939 | 1521380 |
| &nbsp;&nbsp;&nbsp; Inventories | 670542 | 820893 |
| &nbsp;&nbsp;&nbsp; Prepaids and other current assets | 311984 | 698030 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total current assets | 4574889 | 4985826 |
| Long-term assets |  |  |
| &nbsp;&nbsp;&nbsp; Restricted cash | 1462280 | 1431710 |
| &nbsp;&nbsp;&nbsp; Property, plant and equipment, net | 3397022 | 3297769 |
| &nbsp;&nbsp;&nbsp; Capitalized lease disposal costs, net | 614698 | 639286 |
| &nbsp;&nbsp;&nbsp; Financing lease right-of-use asset |  | 826 |
| &nbsp;&nbsp;&nbsp; Operating lease right-of-use asset | 2785839 | 2047733 |
| &nbsp;&nbsp;&nbsp; Goodwill | 1384255 | 1384255 |
| &nbsp;&nbsp;&nbsp; Patents and other intangibles, net | 3291116 | 3373563 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total long-term assets | 12935210 | 12175142 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total assets | $17510099 | $17160968 |
| Liabilities and Stockholders' Equity |  |  |
| Current liabilities |  |  |
| &nbsp;&nbsp;&nbsp; Accounts payable | $935026 | $861883 |
| &nbsp;&nbsp;&nbsp; Accrued liabilities | 1254250 | 1494665 |
| &nbsp;&nbsp;&nbsp; Unearned revenue | 568816 | 513317 |
| &nbsp;&nbsp;&nbsp; Current portion of operating lease right-of-use liability | 189780 | 150532 |
| &nbsp;&nbsp;&nbsp; Current installments of notes payable | 160385 | 308399 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total current liabilities | 3108257 | 3328796 |
| Long-term liabilities |  |  |
| &nbsp;&nbsp;&nbsp; Accrued long-term liabilities | 18750 | 37500 |
| &nbsp;&nbsp;&nbsp; Related party notes payable, net of current portion | 1620000 | 1620000 |
| &nbsp;&nbsp;&nbsp; Notes payable, net of current portion | 215414 | 278897 |
| &nbsp;&nbsp;&nbsp; Asset retirement obligation | 1581198 | 1544788 |
| &nbsp;&nbsp;&nbsp; Operating lease right-of-use liability, net of current portion | 2637598 | 1940979 |
| &nbsp;&nbsp;&nbsp; Mandatorily redeemable convertible preferred stock | 4063000 | 4063000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total long-term liabilities | 10135960 | 9485164 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total liabilities | 13244217 | 12813960 |
| Stockholders' equity |  |  |
| &nbsp;&nbsp;&nbsp; Common stock, $0.01 par value; 750,000,000 shares authorized; 528,010,308 and 523,553,435 shares issued and outstanding, respectively | 5280103 | 5235534 |
| &nbsp;&nbsp;&nbsp; Additional paid in capital | 126580543 | 126432759 |
| &nbsp;&nbsp;&nbsp; Accumulated deficit | (127594764) | (127321285) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total equity | 4265882 | 4347008 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total liabilities and stockholders' equity | $17510099 | $17160968 |

---

See accompanying notes to condensed consolidated financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3

------

[**Table of Contents**](#toc)

**INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES**

**Unaudited Condensed Consolidated Statements of Operations**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Three months ended June 30,*** | ***Three months ended June 30,*** | ***Six months ended June 30,*** | ***Six months ended June 30,*** |
|  | ***2025*** | ***2024*** | ***2025*** | ***2024*** |
| Sale of product | $3655320 | $3169233 | $6894220 | $6073691 |
| Cost of product | 1513761 | 1151722 | 2720624 | 2190069 |
| Gross profit | 2141559 | 2017511 | 4173596 | 3883622 |
| Operating costs and expenses: |  |  |  |  |
| Salaries and contract labor | 1088832 | 961842 | 2208158 | 1902345 |
| General, administrative, and consulting | 1084907 | 1047063 | 1955931 | 2050620 |
| Research and development | 102661 | 188730 | 209364 | 376977 |
| Total operating expenses | 2276400 | 2197635 | 4373453 | 4329942 |
| Net operating loss | (134841) | (180124) | (199857) | (446320) |
| Other income (expense): |  |  |  |  |
| Other income | 38095 | (5344) | 52444 | 155376 |
| Interest income | 18768 | 33531 | 40592 | 66259 |
| Interest expense | (82807) | (81508) | (166658) | (162811) |
| Total other (expense) income | (25944) | (53321) | (73622) | 58824 |
| Net Loss | $(160785) | $(233445) | $(273479) | $(387496) |
| Net loss per common share - basic: | $— | $— | $— | $— |
| Net loss per common share - diluted: | $— | $— | $— | $— |
| Weighted average common shares outstanding - basic | 527355415 | 522779643 | 525718720 | 521473413 |
| Weighted average common shares outstanding - diluted | 527355415 | 522779643 | 525718720 | 521473413 |

---

See accompanying notes to condensed consolidated financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4

------

[**Table of Contents**](#toc)

**INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES**

**Unaudited Condensed Consolidated Statements of Cash Flows**

---

| | | |
|:---|:---|:---|
|  | ***Six months ended June 30,*** | ***Six months ended June 30,*** |
|  | ***2025*** | ***2024*** |
| Cash flows from operating activities |  |  |
| &nbsp;&nbsp;&nbsp; Net loss | $(273479) | $(387496) |
| &nbsp;&nbsp;&nbsp; Adjustments to reconcile net loss to net cash provided by operating activities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depreciation and amortization | 198982 | 200422 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accretion of obligation for lease disposal costs | 36410 | 34753 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Equity based compensation | 65797 | 84400 |
| Gain on sale of property, plant, and equipment |  | (13492) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Right-of-use asset changes, net | (2239) | (2238) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accounts receivable | (211559) | 333311 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inventories | 150351 | 227840 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prepaids and other current assets | 386046 | 363258 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accounts payable and accrued liabilities | (95362) | (352984) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unearned revenues | 55499 | (199177) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net cash provided by operating activities | 310446 | 288597 |
| Cash flows from investing activities: |  |  |
| Proceeds from sale of property, plant, and equipment |  | 36000 |
| &nbsp;&nbsp;&nbsp; Purchase of property, plant and equipment | (190374) | (214936) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net cash used in investing activities | (190374) | (178936) |
| Cash flows from financing activities: |  |  |
| &nbsp;&nbsp;&nbsp; Proceeds from sale of stock and exercise of options and warrants | 10896 | 4865 |
| &nbsp;&nbsp;&nbsp; Payments on financing lease |  | (1523) |
| Proceeds from the issuance of notes payable | 45515 |  |
| &nbsp;&nbsp;&nbsp; Principal payments on notes payable | (232012) | (94365) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net cash used in financing activities | (175601) | (91023) |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | (55529) | 18638 |
| Cash, cash equivalents, and restricted cash at beginning of period | 3377233 | 3568893 |
| Cash, cash equivalents, and restricted cash at end of period | $3321704 | $3587531 |
| Supplemental disclosure of cash flow activities: |  |  |
| &nbsp;&nbsp;&nbsp; Cash paid for interest | $156384 | $155681 |
| &nbsp;&nbsp;&nbsp; Cash paid for income taxes | $66 | $— |
| Supplemental disclosure of noncash financing and investing transactions |  |  |
| Decrease in current installments of notes payable for issuance of stock | $25000 | $— |
| &nbsp;&nbsp;&nbsp; Increase in operating lease right-of-use asset and right-of-use liability for new lease | $830720 | $— |
| &nbsp;&nbsp;&nbsp; Decrease in accrued interest and increase in equity for conversion of dividends to stock | $90660 | $90420 |

---

Reconciliation of cash, cash equivalents, and restricted cash as shown in the condensed consolidated statements of cash flows is presented in the table below:

---

| | | |
|:---|:---|:---|
|  | ***June 30,*** | ***June 30,*** |
|  | ***2025*** | ***2024*** |
| Cash and cash equivalents | $1859424 | $2191108 |
| Restricted cash included in long-term assets | 1462280 | 1396423 |
| Total cash, cash equivalents, and restricted cash shown in statement of cash flows | $3321704 | $3587531 |

---

See accompanying notes to condensed consolidated financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5

------

[**Table of Contents**](#toc)

**INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES**

**Condensed Consolidated Statement of Stockholders' (Deficit) Equity**

**Three and Six Months Ended June 30, 2025**

**(Unaudited)**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | ***Common stock*** | ***Common stock*** |  |  |  |
|  |  |  | ***Additional*** |  |  |
|  | ***Shares*** | ***Common*** | ***Paid-in*** | ***Accumulated*** | ***Total*** |
|  | ***Outstanding*** | ***Stock*** | ***Capital*** | ***Deficit*** | ***(Deficit) Equity*** |
| Balance, January 1, 2025 | 523553435 | $5235534 | $126432759 | $(127321285) | $4347008 |
| Shares issued under employee stock purchase plan | 427305 | 4273 | 6623 |  | 10896 |
| Stock in lieu of dividends on convertible preferred C | 1743457 | 17434 | 73226 |  | 90660 |
| Stock for Amici | 312500 | 3125 | 21875 |  | 25000 |
| Shares issued for issuance of RSUs | 1566771 | 15668 | (15668) |  |  |
| Stock based compensation | 406840 | 4069 | 61728 |  | 65797 |
| Net loss | *—* | *—* | *—* | (273479) | (273479) |
| Balance, June 30, 2025 | 528010308 | $5280103 | $126580543 | $(127594764) | $4265882 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | ***Common stock*** | ***Common stock*** |  |  |  |
|  |  |  | ***Additional*** |  |  |
|  | ***Shares*** | ***Common*** | ***Paid-in*** | ***Accumulated*** | ***Total*** |
|  | ***Outstanding*** | ***Stock*** | ***Capital*** | ***Deficit*** | ***(Deficit) Equity*** |
| Balance, April 1, 2025 | 524794326 | $5247943 | $126525703 | $(127433979) | $4339667 |
| Shares issued under employee stock purchase plan | 274600 | 2746 | 4256 |  | 7002 |
| Stock in lieu of dividends on convertible preferred C | 1624611 | 16246 | 68234 |  | 84480 |
| Shares issued for issuance of RSUs | 1316771 | 13168 | (13168) |  |  |
| Stock based compensation |  |  | (4482) |  | (4482) |
| Net loss | *—* | *—* | *—* | (160785) | (160785) |
| Balance, June 30, 2025 | 528010308 | $5280103 | $126580543 | $(127594764) | $4265882 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6

------

[**Table of Contents**](#toc)

**INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES**

**Condensed Consolidated Statement of Stockholders' (Deficit) Equity**

**Three and Six Months Ended June 30, 2024**

**(Unaudited)**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | ***Common stock*** | ***Common stock*** |  |  |  |
|  |  |  | ***Additional*** |  |  |
|  | ***Shares*** | ***Common*** | ***Paid-in*** | ***Accumulated*** | ***Total*** |
|  | ***Outstanding*** | ***Stock*** | ***Capital*** | ***Deficit*** | ***(Deficit) Equity*** |
| Balance, January 1, 2024 | 519787870 | $5197879 | $126168605 | $(127329859) | $4036625 |
| Shares issued under employee stock purchase plan | 143098 | 1431 | 3434 |  | 4865 |
| Stock in lieu of dividends on convertible preferred C | 1808400 | 18084 | 72336 |  | 90420 |
| Shares issued for issuance of RSUs | 1218250 | 12182 | (12182) |  |  |
| Stock based compensation |  |  | 84400 |  | 84400 |
| Net loss | *—* | *—* | *—* | (387496) | (387496) |
| Balance, June 30, 2024 | 522957618 | $5229576 | $126316593 | $(127717355) | $3828814 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | ***Common stock*** | ***Common stock*** |  |  |  |
|  |  |  | ***Additional*** |  |  |
|  | ***Shares*** | ***Common*** | ***Paid-in*** | ***Accumulated*** | ***Total*** |
|  | ***Outstanding*** | ***Stock*** | ***Capital*** | ***Deficit*** | ***(Deficit) Equity*** |
| Balance, April 1, 2024 | 521889765 | $5218898 | $126302135 | $(127483910) | $4037123 |
| Shares issued under employee stock purchase plan | 99603 | 996 | 2390 |  | 3386 |
| Shares issued for issuance of RSUs | 968250 | 9682 | (9682) |  |  |
| Stock based compensation |  |  | 21750 |  | 21750 |
| Net loss | *—* | *—* | *—* | (233445) | (233445) |
| Balance, June 30, 2024 | 522957618 | $5229576 | $126316593 | $(127717355) | $3828814 |

---

See accompanying notes to the condensed consolidated financial statements

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7

------

[**Table of Contents**](#toc)

**INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES**

**Notes to Unaudited Condensed Consolidated Financial Statements**

**June 30, 2025**

(*1*)&nbsp;&nbsp;&nbsp;&nbsp; The Company and Basis of Presentation

International Isotopes Inc. (INIS) was incorporated in Texas in *November 1995.* The accompanying unaudited condensed consolidated financial statements are presented in conformity with accounting principles generally accepted in the United States of America (GAAP) and include all operations and balances of INIS and its wholly-owned subsidiaries, including International Isotopes Idaho Inc., a Texas corporation; International Isotopes Fluorine Products, Inc., an Idaho corporation; International Isotopes Transportation Services, Inc., an Idaho corporation; RadQual, LLC, a limited liability company (RadQual); RadVent, LLC, a limited liability company; Radnostix, LLC, a limited liability company; and TI Services, LLC, a limited liability company (TI Services). RadQual is a global supplier of molecular imaging quality control and calibration devices, and is based at INIS headquarters in Idaho Falls, Idaho. TI Services is headquartered in Boardman, Ohio and distributes products for nuclear medicine, nuclear cardiology, and Positron Emission Tomography (PET) imaging. INIS, and its wholly-owned subsidiaries are collectively referred to herein as the "Company," "we," "our" or "us."

*Nature of Operations* – The Company manufactures a full range of nuclear medicine calibration and reference standards, a wide range of products, including cobalt teletherapy sources, and an FDA-approved radiopharmaceutical drug product. The Company also holds several patents for a fluorine extraction process that would be used in conjunction with a proposed commercial depleted uranium de-conversion facility which would be located in Lea County, New Mexico (the "De-Conversion Facility"). For *2025*, the Company's business consists of five major business segments: Theranostics Products, Cobalt Products, Nuclear Medicine Standards, Medical Devices, and Fluorine Products. The Company's headquarters and all operations, with the exception of TI Services, are located in Idaho Falls, Idaho.

With the exception of certain unique products, the Company's normal operating cycle is considered to be *one* year. Due to the time required to produce some cobalt products, the Company's operating cycle for those products is considered to be *two* to *three* years. Accordingly, preliminary payments received on cobalt contracts, where shipment will *not* take place for greater than *one* year, have been recorded as unearned revenue and, depending upon estimated ship dates, classified under either current or long-term liabilities on the Company's condensed consolidated balance sheets. These unearned revenues are being recognized as revenue in the periods during which the cobalt shipments take place. All assets expected to be realized in cash or sold during the normal operating cycle of business are classified as current assets.

*Principles of Consolidation* – The accompanying unaudited condensed consolidated financial statements are presented in conformity with GAAP and include all operations and balances of INIS and its wholly-owned subsidiaries including RadQual and TI Services. See Note *4* "Investment and Business Consolidation" for additional information. All significant intercompany accounts and transactions have been eliminated in consolidation.

*Interim Financial Information* – The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Accordingly, the accompanying unaudited condensed consolidated financial statements do *not* include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments and reclassifications considered necessary in order to make the financial statements *not* misleading and for a fair and comparable presentation have been included and are of a normal recurring nature. Operating results for the *three* and *six* months ended *June 30, 2025* are *not* necessarily indicative of the results that *may* be expected for the year ending *December 31, 2025* or any future periods. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company's Annual Report on Form *10*-K for the year ended *December 31, 2024* filed with the SEC on *March 3, 2025.*

*Recent Accounting Pronouncements* – In *December 2023,* Financial Accounting Standards Board issued ASU *2023*-*09, Income Taxes (Topic *740*) - Improvements to Income Tax Disclosures*, which enhances the disclosures required for income taxes in the Company's annual consolidated financial statements. Notably, this ASU requires entities to disclose specific categories in the effective tax rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. ASU *2023*-*09* is effective for the Company in its annual reporting for fiscal *2025* on a prospective basis. Early adoption and retrospective reporting are permitted. The Company is currently evaluating the impact of ASU *2023*-*09* on its consolidated financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *8*

------

[**Table of Contents**](#toc)

(*2*)&nbsp;&nbsp;&nbsp;&nbsp; Current Developments and Liquidity

*Business Condition* – Since inception, the Company has incurred substantial losses. During the *six* months ended *June 30, 2025*, the Company reported a net loss of $273,479 and net cash provided by operating activities of $310,446. During the *six* months ended *June 30, 2024*, the Company reported net loss of $387,496 and net cash provided by operating activities of $288,597.

During the *three* and *six* months ended *June 30, 2025*, the Company continued its focus on its strongest long-standing core business segments which consist of its Theranostics Products (previously called Radiochemical Products), Cobalt Products, and Nuclear Medicine Standards, and in particular, the pursuit of new business opportunities within those segments. Additionally, the Company has begun to focus on the start-up of its Medical Device segment which includes assets purchased from AMICI, Inc. (AMICI) in *2023* and investing into an EasyFill Automated Iodine Capsule System.

The Company holds a Nuclear Regulatory Commission (NRC) construction and operating license for the depleted uranium facility in, as well as the property agreement with, Lea County, New Mexico, where the plant is intended to be constructed. The NRC license for the de-conversion facility is a *forty* (40) year operating license and is the *first* commercial license of this type issued in the United States. On *February 8, 2024,* the Company entered into a definitive agreement to sell all of its assets related to the Fluorine Products segment and the Planned Uranium De-Conversion Facility, including the Lea County land. The definitive agreement provides that the maximum date for closing is *March 31, 2026 (*the "Outside Date"), subject to further extension pursuant to the terms of the agreement. In *July 2025,* the Buyer requested an extension of the Outside Date, which the Company determined was *not* in the best interests of the Company, and therefore, the Outside Date remains *March 31, 2026.* Closing is contingent on various conditions being met, including the Buyer obtaining financing plus approvals and agreements with the NRC and other *third* parties. Proceeds from this sale if it closes by the Outside Date would be $12.5 million in total.

The Company expects that cash from operations, equity or debt financing, and its current cash balance will be sufficient to fund operations for the next *twelve* months. Future liquidity and capital funding requirements will depend on numerous factors, including commercial relationships, technological developments, market factors, available credit, and management of redeemable convertible preferred stock. There is *no* assurance that additional capital and financing will be available on acceptable terms to the Company or at all.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *9*

------

[**Table of Contents**](#toc)

(*3*)&nbsp;&nbsp;&nbsp;&nbsp; Net Income (Loss) Per Common Share - Basic and Diluted

For the *three* and *six* months ended *June 30, 2025*, the Company had 26,662,500 stock options outstanding, 3,000,000 restricted stock units outstanding, and 4,063 outstanding shares of Series C redeemable convertible preferred stock (Series C Preferred Stock), each of which were *not* included in the computation of diluted income (loss) per common share because they would be anti-dilutive.

For the *three* and *six* months ended *June 30, 2024*, the Company had 27,862,500 stock options outstanding, 5,250,000 restricted stock units outstanding, and 4,063 outstanding shares of Series C Preferred Stock, each of which were *not* included in the computation of diluted income (loss) per common share because they would be anti-dilutive.

The table below shows the calculation of diluted shares:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***3 Months Ended*** | ***3 Months Ended*** | ***6 Months Ended*** | ***6 Months Ended*** |
|  | ***June 30,*** | ***June 30,*** | ***June 30,*** | ***June 30,*** |
|  | ***2025*** | ***2024*** | ***2025*** | ***2024*** |
| Weighted average common shares outstanding - basic | 527355415 | 522779643 | 525718720 | 521473413 |
| Effects of dilutive shares |  |  |  |  |
| Stock Options |  |  |  |  |
| Series C Preferred Stock |  |  |  |  |
| Weighted average common shares outstanding - diluted | 527355415 | 522779643 | 525718720 | 521473413 |

---

The table below summarizes common stock equivalents outstanding at *June 30, 2025* and *June 30, 2024*:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***June 30,*** | ***June 30,*** | ***June 30,*** | ***June 30,*** |
|  | ***2025*** | ***2025*** | ***2024*** | ***2024*** |
| Stock options |  | 26662500 |  | 27862500 |
| Restricted Stock Units |  | 3000000 |  | 5250000 |
| Shares of Series C Preferred Stock |  | 40630000 |  | 40630000 |
|  |  | 70292500 |  | 73742500 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *10*

------

[**Table of Contents**](#toc)

(*4*)&nbsp;&nbsp;&nbsp;&nbsp; Investment and Business Consolidation

In *June 2023,* the Company acquired several medical devices with related assets and intellectual property rights from AMICI and has been working on FDA *510k* transfers, and start-up of manufacturing. In *January 2025,* the parties amended the Asset Purchase Agreement whereby the Company received additional product rights and related assets to make up for a shortfall by AMICI in deliverable assets originally contemplated in the Asset Purchase Agreement.

On *June 3, 2024,* the Company entered into a Strategic Development and Distribution Agreement with Alpha Nuclide Inc for the rights to manufacture and distribute the Company's Theranostics Products and Nuclear Medicine Products in mainland China as part of a *50/50* joint Venture between the Company and Alpha Nuclides. The parties will begin with the distribution of the Company's Nuclear Medicine Products as part of phase I of the strategic alliance, with further planned milestones for the establishment of a joint venture to register the Company's Theranostics & Nuclear Medicine Products with the CFDA for local manufacturing and distribution. The parties envision commercializing INIS's radiopharmaceutical Iodine-*131,* radiochemical API, and theranostics API I-*131* for *3*<sup>rd</sup> party therapeutic applications in China. The parties intend to manufacture and distribute the products from Alpha Nuclide's Jiaxing facility, which Alpha Nuclides is responsible for establishing. The parties also intend to enter into a supply agreement for raw material isotopes to be supplied from Alpha Nuclide to the Company to be used in the Company's manufacturing process at the Company's Idaho Falls, Idaho facility.

On *August 6, 2024,* the Company entered into a joint venture agreement with Phantech LLC to form PhanQual. PhanQual will leverage INIS's and Phantech's technologies, facilities, experience, and global network to design, manufacture, and distribute sealed sources, including adapting Phantech's patented and cutting-edge fillable calibration source technology, into sealed source calibration devices to better serve the R&D and theranostics community. Additionally, RadQual will globally distribute Phantech's entire portfolio of fillable sources through RadQual's global network of distributors. PhanQual's revenues and operations will operate through RadQual and will be included in our Nuclear Medicine Standards segment.

(*5*)&nbsp;&nbsp;&nbsp;&nbsp; Stockholders' Equity, Options, and Warrants

<u>Employee Stock Purchase Plan</u>

The Company has an employee stock purchase plan pursuant to which employees of the Company *may* participate to purchase shares of common stock at a discount. During the *six* months ended *June 30, 2025* and *2024*, the Company issued 427,305 and 143,098 shares of common stock, respectively, to employees under the employee stock purchase plan for proceeds of $10,896 and $4,865, respectively. As of *June 30, 2025*, 1,682,924 shares of common stock remain available for issuance under the employee stock purchase plan.

<u>Stock-Based Compensation Plans</u>

*2015* Incentive Plan* - In *April 2015,* the Company's Board of Directors approved the International Isotopes Inc. *2015* Incentive Plan (as amended, the *2015* Plan), which was subsequently approved by the Company's shareholders in *July 2015.* The *2015* Plan was amended and restated in *July 2018* to increase the number of shares authorized for issuance under the *2015* Plan by an additional 20,000,000 shares. The *2015* Plan provides for the grant of incentive and non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance shares and units, and other stock or cash-based awards. At *June 30, 2025*, there were 18,875,685 shares available for issuance under the *2015* Plan.

*Employee/Director Grants* - The Company accounts for issuances of stock-based compensation to employees by recognizing, as compensation expense, the cost of employee services received in exchange for equity awards. The compensation expense is based on the grant date fair value of the award. Stock option compensation expense is recognized over the period during which an employee is required to provide service in exchange for the award (the vesting period).

*Non-Employee Grants* - The Company accounts for its issuances of stock-based compensation to non-employees by recognizing compensation expense based on the grant date fair value of the award. Stock option compensation expense is recognized over the vesting period for the award.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *11*

------

[**Table of Contents**](#toc)

Option awards outstanding as of *June 30, 2025*, and changes during the *six* months ended *June 30, 2025*, were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  |  | ***Weighted*** |  |
|  |  | ***Weighted*** | ***Average*** |  |
|  |  | ***Average*** | ***Remaining*** | ***Aggregate*** |
| **Fixed Options** | ***Shares*** | ***Exercise Price*** | ***Contractual Life*** | ***Intrinsic Value*** |
| Outstanding at December 31, 2024 | 26087500 | $0.05 | 6.1 |  |
| Granted | 700000 | 0.05 |  |  |
| Exercised |  |  |  |  |
| Expired |  |  |  |  |
| Forfeited | 125000 | 0.04 |  |  |
| Outstanding at June 30, 2025 | 26662500 | 0.05 | 5.6 | $907300 |
| Exercisable at June 30, 2025 | 19942500 | $0.05 | 4.7 | $657100 |

---

The intrinsic value of outstanding and exercisable shares is based on the closing price of the Company's common stock on the OTCQB of $0.05 per share on *June 30, 2025*.

As of *June 30, 2025*, there was $77,805 of unrecognized compensation expense related to stock options that will be recognized over a weighted-average period of 1.72 years.

Total stock-based compensation expense for the *six* months ended *June 30, 2025* and *2024* was $65,797 and $84,400, respectively.

During the *six* months ended *June 30, 2025*, the Company granted an aggregate of 700,000 qualified stock options to *eight* of its employees. These options vest over a five-year period with the *first* vesting on the *first* anniversary of the date of grant, with an expiration at the ten-year anniversary for each grant. The exercise price for these granted options was between $0.04 and $0.06 per share. The options issued during the *six* months ended *June 30, 2025* have a fair value of $23,101 as estimated on the date of issue using the Black-Scholes options pricing model with the following weighted-average assumptions: risk free interest rate of 3.95% to 4.52%, expected dividend yield rate of 0%, expected volatility of 72.53% to 85.29% and an expected life between 5 and 7 years.

Restricted Stock Units outstanding as of *June 30, 2025*, and changes during the *six* months ended *June 30, 2025*, were as follows:

---

| | | |
|:---|:---|:---|
| **Non-Vested Restricted Stock Units** | ***Number of restricted stock units*** | ***Weighted average grant-date fair value*** |
| Outstanding at December 31, 2024 | 5250000 | $0.04 |
| Granted |  |  |
| Vested and Exercised | (2250000) | 0.04 |
| Forfeited / Cancelled |  |  |
| Outstanding at June 30, 2025 | 3000000 | $0.04 |

---

As of *June 30, 2025*, there was $31,861 of unrecognized compensation expense related to Restricted Stock Units that will be recognized over a weighted-average period of 0.80 years.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *12*

------

[**Table of Contents**](#toc)

<u>Preferred Stock</u>

At *June 30, 2025*, there were 4,063 shares of the Series C Preferred Stock outstanding with a mandatory redemption date of *February 28, 2027* at $1,000 per share in either cash or shares of common stock, at the option of the holder. Holders of the Series C Preferred Stock do *not* have any voting rights except as required by law and in connection with certain events as set forth in the Statement of Designation of the Series C Preferred Stock. The Series C Preferred Stock accrues dividends at a rate of 6% per annum, payable annually on *February 17th* of each year. The Series C Preferred Stock are convertible at the option of the holders at any time into shares of the Company common stock at an initial conversion price equal to $0.10 per share, subject to adjustment. If the volume-weighted average closing price of the Company's common stock over a period of *90* consecutive trading days is greater than $0.25 per share, the Company *may* redeem all or any portion of the outstanding Series C Preferred Stock at the original purchase price per share plus any accrued and unpaid dividends, payable in shares of common stock.

During the *six* months ended *June 30, 2025* and *2024*, dividends paid to holders of the Series C Preferred Stock totaled $243,780 and $243,030 respectively. Some holders of the Series C Preferred Stock elected to settle their dividend payments with shares of the Company's common stock in lieu of cash. For the *six* months ended *June 30, 2025* and *2024*, the Company issued an aggregate of 1,743,457 and 1,808,400 shares of common stock in lieu of dividend payments of $90,660 and $90,420, respectively, with the remaining dividend payable settled in cash of $153,120 and $152,610, respectively.

(*6*) &nbsp;&nbsp;&nbsp;&nbsp; Debt

In *December 2013,* the Company entered into a promissory note agreement with its then Chairman of the Board and *one* of our major shareholders, pursuant to which we borrowed $500,000 (the *2013* Promissory Note). The *2013* Promissory Note is secured and bears interest at 6% per annum and was originally due *June 30, 2014.* According to the terms of the *2013* Promissory Note, at any time, the lenders *may* settle any or all of the principal and accrued interest with shares of our common stock. In *December 2019,* the *2013* Promissory Note was modified to extend the maturity date to *December 31, 2021,* with all remaining terms unchanged. In *January 2022,* the *2013* Promissory Note was modified to extend the maturity date to *December 31, 2023,* with all remaining terms unchanged. In *February 2024,* the *2013* Promissory Note was modified to extend the maturity date to *March 31, 2026,* with all remaining terms unchanged. In *August 2025,* the *2013* Promissory Note was modified to extend the maturity date to *March 31, 2028,* with all remaining terms unchanged. At *June 30, 2025*, accrued interest payable on the *2013* Promissory Note was $346,734.

In *April 2018,* the Company borrowed $120,000 from its then Chief Executive Officer and Chairman of the Board pursuant to a promissory note (the *2018* Promissory Note). The *2018* Promissory Note accrues interest at 6% per annum, which is payable upon maturity of the *2018* Promissory Note. The *2018* Promissory Note was originally unsecured and originally matured on *August 1, 2018.* At any time, the holder of the *2018* Promissory Note *may* elect to have any or all of the principal and accrued interest settled with shares of our common stock based on the average price of the shares over the previous *20* trading days. In *June 2018,* the *2018* Promissory Note was modified to extend the maturity date to *March 31, 2019* with all other provisions remaining unchanged. In *February 2019,* the *2018* Promissory Note was modified to extend the maturity date to *July 31, 2019* with all other provisions remaining unchanged. In *July 2019,* the *2018* Promissory Note was modified to extend the maturity date to *January 31, 2020* with all other provisions remaining unchanged. In *December 2019,* the *2018* Promissory Note was modified to extend the maturity date to *December 31, 2021,* the note was also modified to become secured by company assets, with all other provisions remaining unchanged. In *December 2021,* the *2018* Promissory Note was modified to extend the maturity date to *December 31, 2023,* with all remaining terms unchanged. In *December 2023,* the *2018* Promissory Note was modified to extend the maturity date to *January 31, 2025,* with all remaining terms unchanged. In *February 2024,* the *2018* Promissory Note was modified to extend the maturity date to *March 31, 2026,* with all remaining terms unchanged. In *August 2025,* the *2018* Promissory Note was modified to extend the maturity date to *March 31, 2028,* with all remaining terms unchanged. At *June 30, 2025*, accrued interest on the *2018* Promissory Note totaled $51,770.

In *December 2019* and *February 2020,* the Company borrowed an aggregate of $1,000,000 from *four* of the Company's major shareholders pursuant to a promissory note (the *2019* Promissory Note). The *2019* Promissory Note bears an interest rate of 4% annually and was originally due *December 31, 2022.* According to the terms of the *2019* Promissory Note, at any time, the lenders *may* settle any or all of the principal and accrued interest with shares of the Company's common stock based on the average closing price of the Company's common stock for the *20* days preceding the payment. In connection with the *2019* Promissory Note, the lenders were issued warrants totaling 30,000,000 warrants to purchase shares of the Company's common stock at $0.045 per share (the Class O Warrants). The fair value of these Class O Warrants issued totaled $446,079 and was recorded as a debt discount and was amortized over the life of the *2019* Promissory Note. The Company calculated a beneficial conversion feature of $315,643 which was accreted to interest expense over the life of the *2019* Promissory Note. In *December 2022,* the *2019* Promissory Note was modified to extend the maturity date to *December 31, 2024,* with all remaining terms unchanged. In *February 2024,* the *2019* Promissory Note was modified to extend the maturity date to *March 31, 2026,* with all remaining terms unchanged. In *August 2025,* the *2019* Promissory Note was modified to extend the maturity date to *March 31, 2028,* with all remaining terms unchanged. At *June 30, 2025*, the accrued interest on the *2019* Promissory Note totaled $219,131.

In *June 2023,* the Company executed an asset purchase agreement with AMICI for the purchase of medical devices and related assets and intellectual property rights. In connection with the asset purchase agreement, the Company entered a promissory note agreement for $427,100 with AMICI. According to the terms of the note, the Company is required to pay AMICI a minimum of $10,000 per month for a period of 45 months. The amount due is *not* subject to interest until the *25th* month after the anniversary of the closing of the agreement. At *June 30, 2025*, the balance of this note was $187,100.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *13*

------

[**Table of Contents**](#toc)

(*7*)&nbsp;&nbsp;&nbsp;&nbsp; Commitments and Contingencies

<u>Dependence on Third Parties</u>

Sales to the Company's top three customers for the *six* months ended *June 30, 2025* were approximately 32% of its total gross revenue. The Company is making efforts to reduce its dependency on a small number of customers by expanding both domestic and foreign. Approximately 18% of the Company's total gross revenue was from sales from a single customer as part of our Theranostics Products segment.

The production of Cobalt-*60* is dependent upon the U.S. Department of Energy (DOE), and its prime operating contractor, which controls the Advanced Test Reactor (ATR) and laboratory operations at the ATR located outside of Idaho Falls, Idaho. From *2014* to *2024,* the Company had a ten-year contract with the DOE for the irradiation of cobalt targets for the production of cobalt-*60.* The Company was able to purchase cobalt targets as available for a fixed price per target and with an annual 5% escalation in price. The contract term was *October 1, 2014,* through *September 30, 2024.* The DOE have informed the Company that they have secured additional feed stock and remain committed to production of cobalt-*60,* and the Company continues to source cobalt-*60* from the DOE through amendments to the existing contract.

Sales of our most predominant Theranostics Products are dependent upon a few key suppliers. An interruption in production by any of these individual suppliers could have an immediate negative impact upon Theranostics Products sales until material could be purchased from alternate suppliers including obtaining regulatory approval to use material from alternative suppliers if necessary. In the *six*-months ended *June 30, 2025,* we experienced a short supply interruption from our key raw material supplier. In the *six*-months ended *June 30, 2025,* the Company received regulatory approval for an additional supplier. The Company has identified other suppliers and continues to search for additional means to produce and procure certain critical isotopes.

The Nuclear Medicine Reference and Calibration Standard products sold by the Company are dependent upon certain radioisotopes that are supplied to the Company through agreements with several suppliers. A loss of any of these suppliers could adversely affect operating results by causing a delay in production or a possible loss of sales. Beginning in the *six* months ended *June 30, 2024*, there was a global shortage of Cobalt-*57* isotopes, a key isotope for this business segment that resulted in significant lost sales. In the *third* quarter of *2024* our main supply of Cobalt-*57* was restored, and our global isotope supply chain has normalized. In *six* months ended *June 30, 2025,* a global outage of Gadolinium-*153* isotopes, a key isotope for this business segment, resulted in significant lost sales. While the Company continues to work with industry to restart supply of this key isotope, we are uncertain of the timeframe to restore supply.

<u>Contingencies</u>

Because all the Company's business segments involve the handling or use of radioactive material, the Company is required to have an operating license from the NRC and specially trained staff to handle these materials. The Company has amended this operating license numerous times to increase the amount of material permitted within the Company's facility. Although this license does *not* currently restrict the volume of business operations performed or projected to be performed in the upcoming year, additional processing capabilities and license amendments could be implemented that would permit the processing of other reactor-produced radioisotopes by the Company. The financial assurance required by the NRC to support this license has been provided for with a surety bond held with North American Specialty Insurance Company which is supported by a restricted money market account held with Merrill Lynch. At *June 30, 2025*, the balance of this account was $1,462,280.

As noted in Footnote *2* above, on *February 8, 2024,* the Company entered into a definitive agreement to sell all of its assets related to the Fluorine Products segment and the Planned Uranium De-Conversion Facility, including the Lea County land. The definitive agreement provides that the maximum date for closing is the Outside Date (*March 31, 2026),* subject to further extension pursuant to the terms of the agreement. In *July 2025,* the buyer requested an extension of the Outside Date, which the Company determined was *not* in the best interests of the Company, and therefore, the Outside Date remains *March 31, 2026.* Closing is contingent on various conditions being met, including the buyer obtaining financing plus approvals and agreements with the NRC and other *third* parties. Proceeds from this sale if it closes by Outside Date would be $12.5 million in total. The Company has *not* recorded the value of this property as an asset and will *not* do so until such time that material changes to or sufficient progress on the project has been made to meet the Company's obligations under the agreements for permanent transfer of the title.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *14*

------

[**Table of Contents**](#toc)

(*8*) &nbsp;&nbsp;&nbsp;&nbsp; Revenue Recognition

<u>Revenue from Product Sales</u>

The Company's revenue consists primarily of distribution of theranostics including sodium iodide I-*131* drug product, calibration and reference standards manufactured for use in the nuclear medicine industry, and cobalt source manufacturing. With the exception of certain unique products, the Company's normal operating cycle is considered to be *one* year. Due to the time required to produce some cobalt products, the Company's operating cycle for those products is considered to be *two* to *three* years. Accordingly, preliminary payments received on cobalt contracts where shipment has *not* taken place have been recorded as unearned revenue on the Company's condensed consolidated balance sheets and classified under current or long-term liabilities, depending upon estimated ship dates. For the *six* months ended *June 30, 2025*, the Company reported current unearned revenue of $568,816. For the period ended *December 31, 2024*, the Company reported current unearned revenue of $513,317. These unearned revenues will be recognized as revenue in the periods during which the cobalt shipments take place.

<u>Contract Balances</u>

The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. As of *June 30, 2025*, and *December 31, 2024*, accounts receivable totaled $1,732,939 and $1,521,380, respectively. For the *six* months ended *June 30, 2025*, the Company did *not* incur material impairment losses with respect to its receivables.

(*9*) &nbsp;&nbsp;&nbsp;&nbsp; Leases

The Company leases office and warehouse space under operating leases. Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments under the lease. Operating lease, right-of-use assets, and liabilities are recognized at the lease commencement date based on the present value of lease payments over the reasonably certain lease term. The implicit rates with the Company's operating leases are generally *not* determinable and the Company uses its incremental borrowing rate at the lease commencement date to determine the present value of its lease payments. The determination of the Company's incremental borrowing rate requires judgement. The company determines its incremental borrowing rate for each lease using its then-current borrowing rate. Certain of the Company's leases include options to extend or terminate the lease. The Company establishes the number of renewal options periods used in determining the operating lease term based upon its assessment at the inception of the operating lease. The option to renew the lease *may* be automatic, at the option of the Company, or mutually agreed to between the landlord and the Company. Once the facility lease term has begun, the present value of the aggregate future minimum lease payments is recorded as a right-of-use asset. Lease expense is recognized on a straight-line basis over the term of the lease.

In *January 2025,* the Company entered into a new operating lease agreement for a *second* facility across the street from its main headquarters. The initial term of the lease is five years, ending *December 2029* and includes the option to extend the lease for *two* additional terms of five years each. The monthly lease rate increases annually by 3% each year. The Company has the right of *first* refusal on this property that allows it to match any offer to purchase this property. The Company recorded an operating lease right-of-use asset and corresponding operating lease right-of-use liability of $830,720 for this lease based on a life of 15 years and incremental borrowing rate of 6.75%.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *15*

------

[**Table of Contents**](#toc)

---

| | | |
|:---|:---|:---|
|  | ***Six Months Ended June 30,*** | ***Six Months Ended June 30,*** |
|  | ***2025*** | ***2024*** |
| Operating lease costs | $187414 | $143554 |
| Short-term operating lease costs | 8408 | 4658 |
| Financing lease expense: |  |  |
| &nbsp;&nbsp;&nbsp; Amortization of right-of-use assets |  | 1523 |
| &nbsp;&nbsp;&nbsp; Interest on lease liabilities |  | 74 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total financing lease expense |  | 1597 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total lease expense | $195822 | $149809 |
| Right-of-use assets obtained in exchange for new operating lease liabilities | $830720 | $— |
| Right-of-use assets obtained in exchange for new financing lease liabilities | $— | $— |
| Weighted-average remaining lease term (years) - operating leases | 11.2 | 10.6 |
| Weighted-average remaining lease term (years) - financing leases | *—* | 0.4 |
| Weighted-average discount rate - operating leases | 6.75% | 6.75% |
| Weighted-average discount rate - financing leases |  | 6.75% |

---

The future minimum payments under these operating lease agreements are as follows:

---

| | | |
|:---|:---|:---|
|  | ***Operating Leases*** | ***Financing Leases*** |
| 2025 (excluding the six-months ended June 30, 2025) | $187414 | $— |
| 2026 | 374828 |  |
| 2027 | 374828 |  |
| 2028 | 374828 |  |
| 2029 | 374828 |  |
| Thereafter | 2328178 |  |
| &nbsp;&nbsp;&nbsp; Total minimum lease obligations | 4014904 |  |
| Less-amounts representing interest | (1187526) |  |
| &nbsp;&nbsp;&nbsp; Present value of minimum lease obligations | 2827378 |  |
| Current maturities | (189780) |  |
| Lease obligations, net of current maturities | $2637598 | $— |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *16*

------

[**Table of Contents**](#toc)

(*10*)&nbsp;&nbsp;&nbsp;&nbsp; Segment Information

The Company's reportable segments are reported in a manner consistent with the way management evaluates the businesses. The results of operations are regularly reviewed by the Company's chief operating decision maker ("CODM"), the Chief Executive Officer. The Company identifies its reportable business segments based on differences in products and services. The accounting policies of the business segments are the same as those described in the summary of significant accounting policies. In order to evaluate each reportable segment's performance, the CODM uses income from operations as a measure of profit and loss. The CODM compares operational performance against management expectations when making decisions regarding allocation of operating and capital resources to each segment.

In *2025*, the Company has five reportable segments which include: Theranostics Products, Cobalt Products, Nuclear Medicine Standards, Medical Device Products, and Fluorine Products. Information regarding the operations and assets of these reportable business segments is contained in the following table:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Three months ended June 30,*** | ***Three months ended June 30,*** | ***Six months ended June 30,*** | ***Six months ended June 30,*** |
| Sale of Product | ***2025*** | ***2024*** | ***2025*** | ***2024*** |
| Theranostics Products | $1905402 | $2169131 | $3692456 | $4074213 |
| Cobalt Products | 678015 | 592199 | 750465 | 826167 |
| Nuclear Medicine Standards | 1013814 | 407903 | 2340580 | 1173311 |
| Medical Device Products | 58089 |  | 110719 |  |
| Fluorine Products |  |  |  |  |
| Total Segments | 3655320 | 3169233 | 6894220 | 6073691 |
| Corporate revenue |  |  |  |  |
| Total Consolidated | $3655320 | $3169233 | $6894220 | $6073691 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Three months ended June 30,*** | ***Three months ended June 30,*** | ***Six months ended June 30,*** | ***Six months ended June 30,*** |
| Depreciation and Amortization | ***2025*** | ***2024*** | ***2025*** | ***2024*** |
| Theranostics Products | $9895 | $5697 | $18104 | $14743 |
| Cobalt Products | 16360 | 23527 | 32362 | 27414 |
| Nuclear Medicine Standards | 31480 | 32866 | 61360 | 61419 |
| Medical Device Products |  |  |  |  |
| Fluorine Products | 26095 | 26095 | 52190 | 57940 |
| Total Segments | 83830 | 88185 | 164016 | 161516 |
| Corporate depreciation and amortization | 17207 | 10790 | 34966 | 38906 |
| Total Consolidated | $101037 | $98975 | $198982 | $200422 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Three months ended June 30,*** | ***Three months ended June 30,*** | ***Six months ended June 30,*** | ***Six months ended June 30,*** |
| Segment Income (Loss) | ***2025*** | ***2024*** | ***2025*** | ***2024*** |
| Theranostics Products | $1009387 | $1171390 | $1886381 | $2184854 |
| Cobalt Products | (97040) | 99324 | (245266) | 32999 |
| Nuclear Medicine Standards | (38387) | (377758) | 229176 | (368262) |
| Medical Device Products | (201305) | (83839) | (382974) | (112350) |
| Fluorine Products | 3905 | (26095) | (22254) | (4846) |
| Total Segments | 676560 | 783022 | 1465063 | 1732395 |
| Corporate loss | (837345) | (1016467) | (1738542) | (2119891) |
| Net Income | $(160785) | $(233445) | $(273479) | $(387496) |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Three months ended June 30,*** | ***Three months ended June 30,*** | ***Six months ended June 30,*** | ***Six months ended June 30,*** |
| Expenditures for Segment Assets | ***2025*** | ***2024*** | ***2025*** | ***2024*** |
| Theranostics Products | $4046 | $— | $50561 | $93924 |
| Cobalt Products |  | 39799 | 12835 | 39799 |
| Nuclear Medicine Standards | 57449 |  | 75663 | 49038 |
| Medical Device Products |  |  | 28876 |  |
| Fluorine Products |  |  |  |  |
| Total Segments | 61495 | 39799 | 167935 | 182761 |
| Corporate purchases |  | 4216 | 22439 | 32175 |
| Total Consolidated | $61495 | $44015 | $190374 | $214936 |

---

---

| | | |
|:---|:---|:---|
|  | ***June 30,*** | ***December 31,*** |
| Segment Assets | ***2025*** | ***2024*** |
| Theranostics Products | $1358808 | $992513 |
| Cobalt Products | 122282 | 167881 |
| Nuclear Medicine Standards | 2649344 | 2928814 |
| Medical Device Products | 653882 | 553117 |
| Fluorine Products | 4823549 | 4875738 |
| &nbsp;&nbsp;&nbsp; Total Segments | 9607865 | 9518063 |
| Corporate assets | 7902234 | 7642905 |
| &nbsp;&nbsp;&nbsp; Total Consolidated | $17510099 | $17160968 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *17*

------

[**Table of Contents**](#toc)

(*11*)&nbsp;&nbsp;&nbsp;&nbsp; Subsequent Events

In *August 2025,* the *2013* Promissory Note was modified to extend the maturity date to *March 31, 2028,* with all remaining terms unchanged.

In *August 2025,* the *2018* Promissory Note was modified to extend the maturity date to *March 31, 2028,* with all remaining terms unchanged.

In *August 2025,* the *2019* Promissory Note was modified to extend the maturity date to *March 31, 2028,* with all remaining terms unchanged.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *18*

------

[**Table of Contents**](#toc)

**ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

*This Quarterly Report on Form 10-Q (the* "*Quarterly Report*"*) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding industry prospects and future results of operations or financial position, made in this Quarterly Report are forward-looking statements. Words such as* "*anticipates,*" "*believes,*" "*should,*" "*expects,*" "*future,*" "*intends*" *and similar expressions identify forward-looking statements. Forward-looking statements reflect management*'*s current expectations, plans or projections, and are inherently uncertain. Actual results could differ materially from management's expectations, plans or projections. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this Quarterly Report. Certain risks and uncertainties that could cause our actual results to differ significantly from management*'*s expectations are described in the risk factors set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission (SEC) on March 3, 2025 and in the other reports we file with the SEC. These factors describe some but not all of the factors that could cause actual results to differ significantly from management*'*s expectations. We undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are urged, however, to review the risks and other factors set forth in the reports that we file from time to time with the SEC.*

<u>BUSINESS OVERVIEW</u>

International Isotopes Inc. and its wholly-owned subsidiaries (including RadQual, LLC, TI Services, LLC, RadVent, LLC, and Radnostix, LLC) (collectively, the "Company", "we", "our", or "us") manufacture a full range of nuclear medicine calibration and reference standards, manufacture a range of cobalt products, and distribute sodium iodide I-131 as a generic drug. We own 100% of RadQual, LLC (RadQual), a global supplier of molecular imaging quality control and calibration devices. As TI Services, LLC is a 50/50 joint venture between the Company and RadQual, TI Services, LLC is also a wholly-owned subsidiary of the Company.

Our business consists of the following five business segments:

*Theranostics Products.* Our Theranostics Products segment (formerly called Radiochemical Products) includes production and distribution of various isotopically pure radiopharmaceuticals, APIs, and radiochemicals for medical, industrial, and research applications. The Company produces these products from radioisotopes supplied by its vendors. The Company produces and distributes various products in customized volumes, concentrations, chemical formulations, packages, and specifications tailored to meet FDA specifications or customer and market demands. The Company's FDA approved generic sodium iodide I-131 drug product is the only generic product of this type manufactured in the U.S. and offers customers an attractive domestic alternative to the single existing foreign commercial drug manufacturer. Additionally, this segment includes the Theranostics Products segment of our Radnostix China Joint Venture.

*Cobalt Products.* Our Cobalt Products segment includes the production of bulk cobalt (cobalt-60), fabrication of cobalt capsules for radiation therapy and various industrial applications, and recycling of expended cobalt sources. We are the only company in the U.S. that can provide these unique services.

*Nuclear Medicine Standards*. Our Nuclear Medicine Standards segment consists of various sealed source calibration and reference products, including our own manufactured products, jointly manufactured products, and third-party products. These products are sold through our RadQual subsidiary for use with Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) imaging equipment, patient positioning, radiopharmacy and radiopharmaceutical CDMO lab equipment, pre-clinical imaging equipment, clinical trial or custom geometry applications, and calibration or operational testing of measuring and/or testing equipment industry. Nuclear Medicine Standards products include flood sources, dose calibrators, cylinder phantoms, rod sources, line sources, flexible and rigid rulers, spot markers, pen point markers, and a host of specialty design items. Pre-clinical products include distribution of fillable sources from Phantech and pre-clinical sealed sources via our PhanQual joint venture with Phantech. Calibration & Reference sources include RadQual products for nuclear pharmacies and related lab equipment; the Company also distributes non-medical sources manufactured by its partner, ORANO LEA. The Nuclear Medicine Standards segment also commercializes bulk isotope sales, medical devices, shielding, and accessories related to the Company's sealed source products.

*Medical Devices* Our Medical Devices segment was started in 2024 from assets previously reported as part of the Nuclear Medicine Standards segment. The products for the Medical Devices segment are currently under development. In 2022 the Company entered a joint venture to develop the EasyFill Automated Capsule System, a robotic lab device to be paired with its Theranostics Products. The EasyFill is still in the developmental stage. In 2023, the Company entered an asset purchase agreement with AMICI, Inc. (AMICI) to purchase manufacturing molds, device registrations, trademarks, and all production rights to several AMICI diagnostic and therapeutic products for lung ventilation; this included the Swirler Radioaerosol System and Tru-Fit mouthpiece products. In January 2025, as part of an amendment to the AMICI asset purchase agreement, the Company received the manufacturing molds, device registrations, trademarks, and all production rights to the AMICI line of Xenon System products. The products that will use these acquired assets from AMICI are currently under development and are expected to be released in the second half of 2025 to be sold through its RadVent subsidiary. In 2024, the Company's Medical Devices segment entered into a distribution and servicing agreement with Scintomics for its complete line of radiosynthesis modules

*Fluorine Products.* We established the Fluorine Products segment in 2004 in conjunction with the development and operation of the proposed depleted uranium de-conversion facility in Lea County, New Mexico. Near the end of 2013, due to changes in the nuclear industry, we placed further engineering work for this project on hold. On February 8, 2024, the Company entered into a definitive agreement to sell all of its assets related to the Fluorine Products segment and the Planned Uranium De-Conversion Facility, including the Lea County land ("Flourine Products Asset Sale"). The definitive agreement provides for the maximum date for closing is March 31, 2026 (the "Outside Date"), subject to further extension pursuant to the terms of the agreement. In July 2025, the buyer requested an extension of the Outside Date, which the Company determined was not in the best interests of the Company, and therefore, the Outside Date remains March 31, 2026. Closing is contingent on various conditions being met, including the Buyer obtaining financing plus approvals and agreements with the NRC and other third parties. Proceeds from this sale if it closes by the Outside Date would be $12.5 million in total.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 19

------

[**Table of Contents**](#toc)

<u>RESULTS OF OPERATIONS</u>

*Three Months Ended June 30, 2025, Compared to Three Months Ended June 30, 2024*

Sale of Product for the three months ended June 30, 2025 was $3,655,320 as compared to $3,169,233 for the same period in 2024, an overall increase of $486,087, or approximately 15%. This increase in sales was the result of increased sales in our Nuclear Medicine Standards and Cobalt Products segments partially offset by decreased sales in our Theranostics Products, as discussed in more detail below.

The following table presents a period-to-period comparison of total revenue by segment for the three months ended June 30, 2025 and 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the Three** | **For the Three** |  |  |
|  | **Months Ended** | **Months Ended** |  |  |
|  | **June 30,** | **June 30,** |  |  |
| Sale of Product | **2025** | **2024** | **$ Change** | **% Change** |
| Theranostics Products | $1905402 | $2169131 | $(263729) | -12% |
| Cobalt Products | 678015 | 592199 | 85816 | 14% |
| Nuclear Medicine Standards | 1013814 | 407903 | 605911 | 149% |
| Medical Device Products | 58089 |  | 58089 | 100% |
| Fluorine Products |  |  |  | —% |
| Total Consolidated Sale of Product | $3655320 | $3169233 | $486087 | 15% |

---

Cost of product increased to $1,513,761 for the three months ended June 30, 2025 from $1,151,722 for the same period in 2024. This is an increase of $362,039, or approximately 31%. The increase in cost of product was primarily due to the increased overall sales in the three months ended June 30, 2025. Gross profit for the three months ended June 30, 2025 was $2,141,559, compared to $2,017,511 for the same period in 2024. This represents an increase in gross profit of $124,048, or approximately 6%, compared to the same period in 2024.

The following table presents cost of product and gross profit data for each of our business segments for the three months ended June 30, 2025 and June 30, 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the Three** |  | **For the Three** |  |
|  | **Months Ended** | **% of** | **Months Ended** | **% of** |
|  | **June 30,** | **Total Sales** | **June 30,** | **Total Sales** |
|  | **2025** | **2025** | **2024** | **2024** |
| Total Sale of Product | $3655320 |  | $3169233 |  |
| Cost of Product |  |  |  |  |
| Theranostics Products | $504832 | 14% | $605192 | 19% |
| Cobalt Products | 432727 | 12% | 329675 | 10% |
| Nuclear Medicine Standards | 529354 | 14% | 216855 | 7% |
| Medical Device Products | 46848 | 1% |  |  |
| Fluorine Products |  | —% |  | —% |
| &nbsp;&nbsp;&nbsp; Total Cost of Product | $1513761 | 41% | $1151722 | 36% |
| Gross Profit | $2141559 |  | $2017511 |  |
| Gross Profit % | 59% |  | 64% |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20

------

[**Table of Contents**](#toc)

Total operating costs and expenses in all segments increased approximately 4% to $2,276,400 for the three months ended June 30, 2025, from $2,197,635 for the same period in 2024. This increase of $78,765 was due to an increase in Salaries and Contract Labor expenses due to increased headcount and increased payrates and increased General, Administrative, and Consulting expenses due to one-time waste disposal expenses, partially offset by decreased Research and Development expenses due to reduced legal expenses in three months ended June 30, 2025.

The following table presents a comparison of total operating expenses for the three months ended June 30, 2025 and 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the three** | **For the three** |  |  |
|  | **months ended** | **months ended** |  |  |
|  | **June 30,** | **June 30,** |  |  |
| Operating Costs and Expenses: | **2025** | **2024** | **% change** | **$ change** |
| Salaries and Contract Labor | $1088832 | $961842 | 13% | $126990 |
| General, Administrative and Consulting | 1084907 | 1047063 | 4% | 37844 |
| Research and Development | 102661 | 188730 | (46)% | (86069) |
| Total operating expenses | $2276400 | $2197635 | 4% | $78765 |

---

Other income was $38,095 for the three months ended June 30, 2025 as compared to other loss $5,344 for the same period in 2024. This is an increase of $43,439, or approximately 813% that was due to extension payments as part of the Flourine Products Asset Sale.

Interest expense for the three months ended June 30, 2025 was $82,807, compared to $81,508 for the same period in 2024. This is an increase of $1,299, or approximately 2%. Interest expense includes dividends accrued on our Series C Preferred Stock. As discussed below, we issued Series C Preferred Stock in February 2017 and May 2017. For the three months ended June 30, 2025 and 2024, we accrued dividends payable of $60,945 and $61,695 respectively, which have been recorded as interest expense, which have been recorded as interest expense. See Note 6 "Debt" to our unaudited consolidated financial statements in this Quarterly Report for additional information about our indebtedness and the associated interest expense.

We had a net loss of $160,785 for the three months ended June 30, 2025 compared to net loss of $233,445 for the same period in 2024. This increase in net income of $72,660 is largely the result of increased sales in our Nuclear Medicine Standards Products and Cobalt Products segments partially offset by the decrease in sales in our Theranostics Products for the three months ended June 30, 2025, as compared to the same period in 2024.

*<u>Theranostics Products</u>*. Sales of Theranostics Products for the three months ended June 30, 2025 was $1,905,402, compared to $2,169,131 for the same period in 2024. This is a decrease of $263,729, or approximately 12% during the three months ended June 30, 2025. The decrease was due to additional sales due to a competitor outage during the three months ended June 30, 2024 with no such additional sales in the three months ended June 30, 2025. We expect continued sales growth for our Theranostics Products going forward, primarily from the sale of our generic sodium iodide I-131 drug product and new sales of theranostic API product

Cost of product for Theranostics Products decreased to $504,832 for the three months ended June 30, 2025, as compared to $605,192 for the same period in 2024. This is a decrease of $100,360, or approximately 17%, and was the result of the decreased sales. Gross profit of Theranostics Products for the three months ended June 30, 2025 was $1,400,570, compared to $1,563,939 for the same period in 2024, and gross profit percentage was approximately 74% and 72% for three months ended June 30, 2025 and 2024 respectively. Operating expenses for this segment decreased to $391,183 for the three months ended June 30, 2025, compared to $392,549 for the same period in 2024. This in an decrease in operating expenses of $1,366, or less than 1%. This segment reported net income of $1,009,387 for the three months ended June 30, 2025, as compared to net income of $1,171,390 for the same period in 2024. The decrease in net income of $162,003 is the result of decreases in sales.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 21

------

[**Table of Contents**](#toc)

*<u>Cobalt Products</u>*. Sales of product in the Cobalt Products segment for the three months ended June 30, 2025 was $678,015, compared to $592,199 for the same period in 2024. This represents an increase of $85,816, or approximately 14%. The increase was primarily due to the timing of cobalt sealed source manufacturing sales. Large value sales of high activity cobalt sources occur at various times throughout the year. Frequently the timing of these sales can have a significant impact on period comparisons.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cost of product for the three months ended June 30, 2025, was $432,727, as compared to $329,675, for the same period in 2024. Gross profit for cobalt products for the three months ended June 30, 2025 was $245,288 compared to $262,524 for the same period in 2024. This is a decrease of $17,236, or approximately 7%. Operating costs and expenses in this segment were $342,328 for the three months ended June 30, 2025, compared to $163,200 for the same period in 2024. This increase in operating costs and expenses is due to waste expense of $129,000 in the three months ended June 30, 2025 compared to no such expense in 2024. We had a net loss for Cobalt Products of $97,040 for the three months ended June 30, 2025, as compared to net income of $99,324 for the same period in 2024. The decrease in net income of $196,364, or approximately 198%, was attributable to the additional waste expense in the three months ended June 30, 2025.

*<u>Nuclear Medicine Standards</u>*. Sales of product in the Nuclear Medicine Products segment for the three months ended June 30, 2025, was $1,013,814, compared to $407,903 for the same period in 2024. This represents an increase in sales of $605,911, or approximately 149%. The increase was due to a global shortage of Cobalt-57 isotope during the three months ended June 30, 2024 with no such shortage in the three months ended June 30, 2025. The Cobalt-57 shortage began in January of 2024 and was restored in the third quarter of 2024. We added additional suppliers of Cobalt-57 in 2024.

Cost of product for our nuclear medicine standards segment for the three months ended June 30, 2025, was $529,354, as compared to $216,855 for the same period in 2024. The increase in cost of product in the period-to-period comparison of $312,499, or 144%, was due to increased sales during the three-month period ended June 30, 2025 compared to the same period in 2024. Gross profit for our nuclear medicine standards segment for the three months ended June 30, 2025 was $484,460 compared to $191,048 for the same period in 2024. This is an increase in gross profit of $293,412, or approximately 154%.

Operating costs and expenses for this segment for the three months ended June 30, 2025 decreased to $522,847, from $568,806 for the same period in 2024. This is a decrease of $45,959, or approximately 8%, and was the result of some additional waste expenses that occurred in the three months ended June 30, 2024. Net loss for this segment for the three months ended June 30, 2025 was $38,387, compared to net loss of $377,758 for the same period in 2024. This is an increase in net income of $339,371 and was the result of increased sales.

*<u>Medical Device Products</u>.* For the three months ended June 30, 2025 we had sale of product in the Medical Device Products segment of $58,089 with no sales in the same period ending June 30, 2024. Sale of product in the second quarter of 2025, included distribution of various third-party products. We plan to commercialize additional third-party medical devices and accessories related to the radiopharmaceutical and theranostics spaces and provide engineering, installation, and preventative maintenance and services related to those medical devices. We are also in development for our Swirler® and Tru-Fit™ Mouthpiece products which will be under the branding of RadVent. These products are based on assets and intellectual property rights we acquired previously from AMICI, Inc. Due to the impact of tariff issues, we expect these RadVent products to release in early 2026 instead of late 2025 as previously reported. We also are under development through a joint venture of our EasyFill Automated Iodine Capsule System.

Operating costs and expenses for this segment for the three months ended June 30, 2025 were $212,546 compared to $83,839 in the same period in 2024. This increase in operating expenses of $128,707 was due to increased activity including labor, professional services, and research and development related to the startup of this new business segment. Net loss for this segment for the three months ended June 30, 2025 was $201,305, compared to net loss of $83,839 for the same period in 2024. This is an increase in net loss of $117,466 due to the increased development activity in the segment.

*<u>Fluorine Products</u>.* For the three months ended June 30, 2025 and June 30, 2024, we had no sales in our Fluorine Products segment.

During the three months ended June 30, 2025, we incurred $26,095 of expenses related to maintenance of plans, designs, and other assets for a proposed de-conversion facility, as compared to $26,095 for the same three-month period in 2024.

On February 8, 2024, we entered into the Flourine Products Asset Sale. Upon closing of the Flourine Products Asset Sale, the costs of maintenance for the assets in this segment would not continue. With no assets nor operating activities, this business segment would be phased out. During the three months ended June 30, 2025, we received $30,000 in extension payments related to the Flourine Products Asset Sale. These payments were included in Other Income on our Statement of Operations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 22

------

[**Table of Contents**](#toc)

*Six Months Ended June 30, 2025, Compared to Six Months Ended June 30, 2024*

Sale of Product in all segments for the six months ended June 30, 2025 was $6,894,220 compared to $6,073,691 for the same period in 2024, an overall increase of $820,529, or approximately 14%. This increase in sales was the result of increased sales in our Nuclear Medicine Standards segment partially offset by decreased sales in our Theranostics Products and Cobalt Products, as discussed in more detail below.

The following table presents a period-to-period comparison of total revenue by segment for the six months ended June 30, 2025 and 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the Six** | **For the Six** |  |  |
|  | **Months Ended** | **Months Ended** |  |  |
|  | **June 30,** | **June 30,** |  |  |
| Sale of Product | **2025** | **2024** | **$ Change** | **% Change** |
| Theranostics Products | $3692456 | $4074213 | $(381757) | -9% |
| Cobalt Products | 750465 | 826167 | (75702) | -9% |
| Nuclear Medicine Standards | 2340580 | 1173311 | 1167269 | 99% |
| Medical Device Products | 110719 |  | 110719 | 100% |
| Fluorine Products |  |  |  | —% |
| Total Consolidated Sale of Product | $6894220 | $6073691 | $820529 | 14% |

---

Cost of product in all segments increased to $2,720,624 for the six months ended June 30, 2025 from $2,190,069 for the same period in 2024. This is an increase of $530,555, or approximately 24%. The increase in cost of product in the six-month comparison was primarily due to the increased sales in the six months ended June 30, 2025. Gross profit for the six months ended June 30, 2025 was $4,173,596, compared to $3,883,622 for the same period in 2024. This represents an increase in gross profit of $289,974, or approximately 7%.

The following table presents cost of product and gross profit data for each of our business segments for the six months ended June 30, 2025 and June 30, 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the Six** |  | **For the Six** |  |
|  | **Months Ended** | **% of** | **Months Ended** | **% of** |
|  | **June 30,** | **Total Sales** | **June 30,** | **Total Sales** |
|  | **2024** | **2024** | **2024** | **2024** |
| Total Sale of Product | $6894220 |  | $6073691 |  |
| Cost of Product |  |  |  |  |
| Theranostics Products | $1010000 | 15% | $1181602 | 19% |
| Cobalt Products | 471599 | 7% | 438711 | 7% |
| Nuclear Medicine Standards | 1144824 | 17% | 569756 | 9% |
| Medical Device Products | 94201 | 1% |  | —% |
| Fluorine Products |  | —% |  | —% |
| Total Cost of Product | $2720624 | 39% | $2190069 | 36% |
| Gross Profit | $4173596 |  | $3883622 |  |
| Gross Profit % | 61% |  | 64% |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 23

------

[**Table of Contents**](#toc)

Total operating costs and expenses in all segments increased approximately 1% to $4,373,453 for the six months ended June 30, 2025, from $4,329,942 for the same period in 2024. This increase of $43,511 was due to increases in Salaries and Contract Labor expenses due to increased headcount and increased payrates in six months ended June 30, 2025, partially offset by a decrease General, Administrative, and Consulting expenses due to reduced professional fees and decreased Research and Development expenses due to reduced legal expenses.

The following table presents a comparison of total operating expenses for the six months ended June 30, 2025 and 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the six** | **For the six** |  |  |
|  | **months ended** | **months ended** |  |  |
|  | **June 30,** | **June 30,** |  |  |
| Operating Costs and Expenses: | **2025** | **2024** | **% change** | **$ change** |
| Salaries and Contract Labor | $2208158 | $1902345 | 16% | $305813 |
| General, Administrative and Consulting | 1955931 | 2050620 | (5%) | (94689) |
| Research and Development | 209364 | 376977 | (44%) | (167613) |
| Total operating expenses | $4373453 | $4329942 | 1% | $43511 |

---

Other income in all segments was $52,444 for the six months ended June 30, 2025 as compared to other income $155,376 for the same period in 2024. This is a decrease of $102,932, or approximately 66% that was due to a decrease in miscellaneous income.

Interest expense for the six months ended June 30, 2025 was $166,658, compared to $162,811 for the same period in 2024. This is an increase of $3,847, or approximately 2%. Interest expense includes dividends accrued on our Series C Preferred Stock. As discussed below, we issued Series C Preferred Stock in February 2017 and May 2017. For the six months ended June 30, 2025 and 2024, we accrued dividends payable of $121,890 and $121,140 respectively, which have been recorded as interest expense. See Note 6 "Debt" to our unaudited consolidated financial statements in this Quarterly Report for additional information about our indebtedness and the associated interest expense.

We had a net loss of $273,479 for the six months ended June 30, 2025 compared to net loss of $387,496 for the same period in 2024. This increase in net income of $114,017 was largely the result of increased sales in our Nuclear Medicine Standards segment and increased gross profit percentages partially offset by the decrease in sales in our Theranostics Products and Cobalt Products segments for the six months ended June 30, 2025, as compared to the same period in 2024.

*<u>Theranostics Products</u>*. Sales of product in the Theranostics Products segment for the six months ended June 30, 2025 was $3,692,456, compared to $4,074,213 for the same period in 2024. This is a decrease of $381,757, or approximately 9%. The decrease is the result of a two-week temporary supplier outage during the six months ended June 30, 2025. We expect continued sales growth for our Theranostics Products going forward, primarily from the sale of our generic sodium iodide I-131 drug product and new sales of theranostic API product

Cost of product for Theranostics Products decreased to $1,010,000 for the six months ended June 30, 2025, as compared to $1,181,602 for the same period in 2024. This is a decrease of $171,602, or approximately 15%, and was the result of the decreased sales. Gross profit of Theranostics Products for the six months ended June 30, 2025 was $2,682,456, compared to $2,892,611 for the same period in 2024, and gross profit percentage was approximately 73% and 71% respectively. Operating costs expenses for this segment increased to $796,075 for the six months ended June 30, 2025, compared to $707,757 for the same period in 2024. This in an increase in operating costs and expenses of $88,318, or approximately 12%. This segment reported net income of $1,886,381 for the six months ended June 30, 2025, compared to net income of $2,184,854 for the same period in 2024. The decrease in net income of $298,473 was the result of decreased sales due to a temporary supplier outage and increased operating expenses during the six months ended June 30, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 24

------

[**Table of Contents**](#toc)

*<u>Cobalt Products</u>*. Sales of product in the Cobalt Products segment for the six months ended June 30, 2025 was $750,465, compared to $826,167 for the same period in 2024. This represents a decrease of $75,702, or approximately 9%. The decrease was primarily due to the timing of cobalt sealed source manufacturing sales. Large value sales of high activity cobalt sources occur at various times throughout the year. Frequently the timing of these sales can have a significant impact on period comparisons.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cost of product for the six months ended June 30, 2025, was $471,599, compared to $438,711, for the same period in 2024. Gross profit for Cobalt Products for the six months ended June 30, 2025 was $278,866 compared to $387,456 for the same period in 2024. This is a decrease of $108,590, or approximately 28%. Operating costs and expenses in this segment were $524,132 for the six months ended June 30, 2025, compared to $354,457 for the same period in 2024. This increase was due to waste expenses of $129,000 in the six months ended June 30, 2025. We had a net loss for cobalt products of $245,266 for the six months ended June 30, 2025, as compared to a net income of $32,999 for the same period in 2024. The decrease in net income of $278,265 was attributable decreased sales and increased operating expenses.

*<u>Nuclear Medicine Standards</u>*. Sales from nuclear medicine products for the six months ended June 30, 2025, was $2,340,580, compared to $1,173,311 for the same period in 2024. This represents an increase in sales of $1,167,269, or approximately 99%. The increase was due to a global shortage of Cobalt-57 isotope during the six months ended June 30, 2024 with no such shortage in the six months ended June 30, 2025. The Cobalt-57 shortage began in January of 2024 and was restored in the third quarter of 2024. We added additional suppliers of Cobalt-57 in 2024.

Cost of product for our nuclear medicine standards segment for the six months ended June 30, 2025, was $1,144,824, as compared to $569,756 for the same period in 2024. The increase in cost of sales in the period-to-period comparison of $575,068, or 101%, was due to increased sales during the six-month period ended June 30, 2025, as compared to the same period in 2024. Gross profit for our nuclear medicine standards segment for the six months ended June 30, 2025 was $1,195,756 compared to $603,555 for the same period in 2024. This is an increase in gross profit of $592,201, or approximately 98%.

Operating expenses for this segment for the six months ended June 30, 2025 decreased to $966,580, from $971,817 for the same period in 2024. This is a decrease of $5,237, or approximately 1%. Net income for this segment for the six months ended June 30, 2025 was $229,176, compared to net loss of $368,262 for the same period in 2024. This is an increase in net income of $597,438 and is the result of increased sales.

*<u>Medical Device Products</u>.* For the six months ended June 30, 2025 we had sale of product in the Medical Device Products segment of $110,719 with no sales in the same period ending June 30, 2024. Sale of product in six months ended June 30, 2025 included distribution of various third-party products. We plan to commercialize additional third-party medical devices and accessories related to the radiopharmaceutical and theranostics spaces and provide engineering, installation, and preventative maintenance and services related to those medical devices. We are also in development for our Swirler® and Tru-Fit™ Mouthpiece products which will be under the branding of RadVent. These products are based on assets and intellectual property rights we acquired previously from AMICI, Inc. Due to the impact of tariff issues, we expect these RadVent products to release in early 2026 instead of late 2025 as previously reported. We also are under development through a joint venture of our EasyFill Automated Iodine Capsule System.

Operating costs and expenses for this segment for the six months ended June 30, 2025 were $399,492 as compared to $112,350 in the same period in 2024. This increase in operating expenses of $287,142 is due to increased activity including labor, professional services, and research and development related to the startup of this new business segment. Net loss for this segment for the six months ended June 30, 2025 was $382,974, compared to net loss of $112,350 for the same period in 2024. This is an increase in net loss of $270,624 due to the increased development activity in the segment.

*<u>Fluorine Products</u>.* For the six months ended June 30, 2025 and June 30, 2024, we had no revenue for our fluorine products segment.

During the six months ended June 30, 2025, we incurred $52,254 of expenses related to maintenance of plans, designs, and other assets for a proposed de-conversion facility, compared to $54,846 for the same six-month period in 2024.

On February 8, 2024, we entered into the Flourine Products Asset Sale. Upon closing of the Flourine Products Asset Sale, the costs of maintenance for the assets in this segment would not continue. With no assets nor operating activities, this business segment would be phased out. During the three months ended June 30, 2025, we received $30,000 in extension payments related to the Flourine Products Asset Sale. These payments were included in Other Income on our Statement of Operations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25

------

[**Table of Contents**](#toc)

<u>LIQUIDITY AND CAPITAL RESOURCES</u>

At June 30, 2025, we had cash and cash equivalents of $1,859,424 as compared to $1,945,523 at December 31, 2024. This is a decrease of $86,099 or approximately 4% was largely due to an increase in accounts receivable and principal payments on notes payable. For the six months ended June 30, 2025, net cash provided by operating activities was $310,446 and for the six months ended June 30, 2024, net cash provided by operating activities was $288,597. The increase in cash provided by operating activities was a result of a decrease in net loss in the six months ended June 30, 2025.

Inventories at June 30, 2025 totaled $670,542, and inventories at December 31, 2024 totaled $820,893. Our inventory consists of work in process material for our Theranostics Products, Cobalt Products, Nuclear Medicine Standards, and Medical Device Products segments.

Cash used in investing activities was $190,374 for the six months ended June 30, 2025, and cash used in investing activities was $178,936 for the same period in 2024. The cash used in both periods was for the purchase of equipment.

Cash used in financing activities was $175,601 during the six months ended June 30, 2025, and cash used in financing activities for the same period in 2024 was $91,023. During the six months ended June 30, 2025, cash paid for interest was $156,384 as compared to cash paid for interest of $155,681. for the same six-month period in 2024. Additionally, during the six months ended June 30, 2025, we received $10,896 in proceeds from the sale of our common stock through our Employee Stock Purchase Plan, as compared to $4,865 in proceeds from the sale of our common stock through our Employee Stock Purchase Plan in the six months ended June 30, 2024. During the six months ended June 30, 2025, principal payments on notes payable were $232,012, as compared to $94,365 for the same period in 2024.

In February 2025, we declared our annual dividend on the Series C Preferred Stock. Dividends payable totaled $243,780 at that time. Some holders of the Series C Preferred Stock elected to settle their dividend payments with shares of the Company's common stock in lieu of cash. The Company issued 1,743,457 shares of common stock in lieu of a dividend payment of $90,660. $153,120 of dividend payable was settled with cash.

Total decrease in cash for the six months ended June 30, 2025, was $55,529 compared to a cash increase of $18,638 for the same period in 2024.

We expect that cash from operations, cash raised via equity financing, and our current cash balance will be sufficient to fund operations for the next twelve months. Our future liquidity and capital funding requirements will depend on numerous factors, including commercial relationships, technological developments, market factors, available credit, and preferred stock shareholders. There is no assurance that additional capital and financing will be available on acceptable terms to the Company or at all.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 26

------

[**Table of Contents**](#toc)

*<u>Debt</u>*

In December 2013, we entered into a promissory note agreement with our then Chairman of the Board and one of our major shareholders, pursuant to which we borrowed $500,000 (the 2013 Promissory Note). The 2013 Promissory Note is secured and bears interest at 6% per annum and was originally due June 30, 2014. According to the terms of the 2013 Promissory Note, at any time, the lenders may settle any or all of the principal and accrued interest with shares of our common stock. Pursuit to four modifications in the time period between June 2014 and January 2022, the 2013 Promissory Note was modified to extend the maturity date to December 31, 2023, with all remaining terms unchanged. In February 2024, the 2013 Promissory Note was modified again to extend the maturity date to March 31, 2026, with all remaining terms unchanged. In August 2025, the 2013 Promissory Note was modified again to extend the maturity date to March 31, 2028, with all remaining terms unchanged. At June 30, 2025, accrued interest payable on the 2013 Promissory Note was $346,734.

In April 2018, we borrowed $120,000 from our Chief Executive Officer and Chairman of the Board pursuant to a promissory note (the 2018 Promissory Note). The 2018 Promissory Note is secured and accrues interest at 6% per annum, which is payable upon maturity of the 2018 Promissory Note. At any time, the holders of the 2018 Promissory Note may elect to have any or all of the principal and accrued interest settled with shares of our common stock based on the average price of the shares over the previous 20 trading days. The 2018 Promissory Note was originally due August 1, 2018. Pursuit to six modifications within the period of June 2018 and December 2023, the 2018 Promissory Note was modified to extend the maturity date to January 31, 2025, with all remaining terms unchanged. In February 2024, the 2018 Promissory Note was modified to extend the maturity date to March 31, 2026, with all remaining terms unchanged. In August 2025, the 2018 Promissory Note was modified again to extend the maturity date to March 31, 2028, with all remaining terms unchanged. At June 30, 2025, accrued interest on the 2018 Promissory Note totaled $51,770.

In December 2019 and February 2020, we borrowed an aggregate of $1,000,000 from our Chief Executive Officer, Chairman of the Board, former Chairman of the Board, and one of our major shareholders pursuant to a promissory note (the 2019 Promissory Note). The 2019 Promissory Note bears an interest rate of 4% annually and was originally due December 31, 2022. According to the terms of the 2019 Promissory Note, at any time, the lenders may settle any or all of the principal and accrued interest with shares of the Company's common stock based on the average closing price of the Company's common stock for the 20 days preceding the payment. In December 2022, the 2019 Promissory Note was modified to extend the maturity date to December 31, 2024, with all remaining terms unchanged. In February 2024, the 2019 Promissory Note was modified to extend the maturity date to March 31, 2026, with all remaining terms unchanged. In August 2025, the 2019 Promissory Note was modified again to extend the maturity date to March 31, 2028, with all remaining terms unchanged. At June 30, 2025, the accrued interest on the 2019 Promissory Note totaled $219,131.

In June 2023, we executed an asset purchase agreement with AMICI for the purchase of medical devices and related assets and intellectual property rights. In connection with the asset purchase agreement, we entered a promissory note for $427,100 to AMICI. According to the terms of the note, we are required to pay the seller a minimum of $10,000 per month for a period of 45 months. The amount due is not subject to interest until the 25th month after the anniversary of the closing of the agreement. At June 30, 2025, the balance of this promissory note was $187,100.

<u>CRITICAL ACCOUNTING POLICIES</u> 

From time-to-time, management reviews and evaluates certain accounting policies that are considered to be significant in determining our results of operations and financial position.

A description of the Company's critical accounting policies that affect the preparation of the Company's financial statements is set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 3, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 27

------

[**Table of Contents**](#toc)

**ITEM 4. CONTROLS AND PROCEDURES**

**Evaluation of Disclosure Controls and Procedures**

We maintain disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act), that are designed to ensure that material information relating to us is made known to the officers who certify our financial reports and to other members of senior management and the Board of Directors. These disclosure controls and procedures are designed to ensure that information required to be disclosed in our reports that are filed or submitted under the Exchange Act are recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.

Management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness, as of June 30, 2025, of our disclosure controls and procedures. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of June 30, 2025.

**Changes in Internal Control over Financial Reporting**

There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended June 30, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

**PART II** – **OTHER INFORMATION**

**ITEM 1. LEGAL PROCEEDINGS**

A discussion of legal matters is found in Note 7, "Commitments and Contingencies", in the accompanying notes to the unaudited condensed consolidated financial statements included in Part I - Item 1. Financial Statements of this Quarterly Report.

**ITEM 1A. RISK FACTORS**

There have been no material changes or updates to the risk factors previously disclosed in Item 1A. "Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2024.

**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

None.

**ITEM *5.* OTHER INFORMATION**

During the quarter ended *June 30, 2025*, no director or officer of the Company adopted or terminated a "Rule *10b5*-*1* trading arrangement" or "non-Rule *10b5*-*1* trading arrangement," as each term is defined in Item *408*(a) of Regulation S-K.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *28*

------

[**Table of Contents**](#toc)

**ITEM 6. EXHIBITS**

---

| | |
|:---|:---|
| Exhibit No. | Description |

---

---

| | |
|:---|:---|
| 3.1 | [Restated Certificate of Formation, as amended (incorporated by reference to Exhibit 3.1 of the Company's Quarterly Report on Form 10-Q for quarter ended June 30, 2010).](http://www.sec.gov/Archives/edgar/data/1038277/000115895710000177/exhibit31.htm) |

---

---

| | |
|:---|:---|
| 3.2 | [Statement of Designation of the Series C Convertible Redeemable Preferred Stock of International Isotopes Inc. (incorporated by reference to Exhibit 3.1 of the Company's Current Report on Form 8-K filed on February 24, 2017).](http://www.sec.gov/Archives/edgar/data/1038277/000151597117000030/exhibit31.htm) |

---

---

| | |
|:---|:---|
| 3.3 | [Certificate of Amendment to Statement of Designation of the Series C Convertible Redeemable Preferred Stock International Isotopes Inc., dated February 16, 2022 (incorporated by reference to Exhibit 3.1 of the Company's Current Report on Form 8-K filed on February 22, 2022).](http://www.sec.gov/Archives/edgar/data/1038277/000151597122000039/exhibit31.htm) |

---

---

| | |
|:---|:---|
| 3.4 | [Certificate of Amendment to Statement of Designation of the Series C Convertible Redeemable Preferred Stock International Isotopes Inc., dated December 28, 2022 (incorporated by reference to Exhibit 3.1 of the Company's Current Report on Form 8-K filed December 28, 2022).](http://www.sec.gov/Archives/edgar/data/1038277/000151597122000211/exhibit31.htm) |
| 3.5 | [Certificate of Amendment to Statement of Designation of the Series C Convertible Redeemable Preferred Stock International Isotopes Inc., dated September 26, 2024 (incorporated by reference to Exhibit 3.1 of the Company's Current Report on Form 8-K filed on October 2, 2024).](http://www.sec.gov/Archives/edgar/data/1038277/000143774924030450/ex_729069.htm) |
| 3.6 | [Bylaws (incorporated by reference to Exhibit 3.2 of the Company's Registration Statement on Form SB-2 filed on May 1, 1997 (Registration No. 333-26269)).](http://www.sec.gov/Archives/edgar/data/1038277/0001005477-97-001198.txt) |

---

---

| | |
|:---|:---|
| 31.1\* | [Certification by the Chief Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002.](ex_825316.htm) |

---

---

| | |
|:---|:---|
| 31.2\* | [Certification by the Chief Financial Officer under Section 302 of the Sarbanes-Oxley Act of 2002.](ex_825317.htm) |

---

---

| | |
|:---|:---|
| 32.1\*\* | [Certification by the Chief Executive Officer furnished pursuant to 18 U.S.C. Section 1350 adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ex_825318.htm) |

---

---

| | |
|:---|:---|
| 32.2\*\* | [Certification by the Chief Financial Officer furnished pursuant to 18 U.S.C. Section 1350 adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ex_825319.htm) |

---

---

| | |
|:---|:---|
| 101.INS\* | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |

---

---

| | |
|:---|:---|
| 101.SCH\* | Inline XBRL Taxonomy Extension Schema Document |

---

---

| | |
|:---|:---|
| 101.CAL\* | Inline XBRL Taxonomy Extension Calculation Linkbase Document |

---

---

| | |
|:---|:---|
| 101.DEF\* | Inline XBRL Taxonomy Extension Definition Linkbase Document |

---

---

| | |
|:---|:---|
| 101.LAB\* | Inline XBRL Taxonomy Extension Label Linkbase Document |

---

---

| | |
|:---|:---|
| 101.PRE\* | Inline XBRL Taxonomy Extension Presentation Linkbase Document |

---

---

| | |
|:---|:---|
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101). |

---

------

\* Filed herewith.

\*\* Furnished herewith.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 29

------

[**Table of Contents**](#toc)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: August 13, 2025 | International Isotopes Inc. | International Isotopes Inc. |
|  | By: | /s/ Shahe Bagerdjian |
|  |  | Shahe Bagerdjian |
|  |  | Chief Executive Officer |
|  | By: | /s/ W. Matthew Cox |
|  |  | W. Matthew Cox |
|  |  | Chief Financial Officer |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 30

## Exhibit 31.1

------

------

**Exhibit 31.1**

**CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002**

I, Shahe Bagerdjian, certify that:

1. I have reviewed this quarterly report on Form 10-Q of International Isotopes Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 (e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15 (f) and 15d-15 (f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 13, 2025

<u>/s/ Shahe Bagerdjian</u>

Shahe Bagerdjian, Chief Executive Officer

## Exhibit 31.2

------

------

**Exhibit 31.2**

**CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002**

I, W. Matthew Cox, certify that:

1. I have reviewed this quarterly report on Form 10-Q of International Isotopes Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 (e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15 (f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 13, 2025

<u>/s/ W. Matthew Cox</u>

W. Matthew Cox, Chief Financial Officer

## Exhibit 32.1

------

------

**Exhibit 32.1**

**CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of International Isotopes Inc. and subsidiaries (the "Company") for the period ended June 30, 2025, as filed with the Securities and Exchange Commission (the "Form 10-Q"), I, Shahe Bagerdjian, Chief Executive Officer of the Company, in my capacity as such, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The Form 10-Q fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (15 U.S.C. 78m or 78o(d)); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| August 13, 2025 | /s/ Shahe Bagerdjian |
|  | Shahe Bagerdjian |
|  | Chief Executive Officer |

---

## Exhibit 32.2

------

------

**Exhibit 32.2**

**CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of International Isotopes Inc. and subsidiaries (the "Company") for the period ended June 30, 2025, as filed with the Securities and Exchange Commission (the "Form 10-Q"), I, W. Matthew Cox, Chief Financial Officer of the Company, in my capacity as such, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The Form 10-Q fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (15 U.S.C. 78m or 78o(d)); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| August 13, 2025 | /s/ W. Matthew Cox |
|  | W. Matthew Cox |
|  | Chief Financial Officer |

---